The digital health revolution is accelerating at an unprecedented pace, transforming how we diagnose diseases, deliver care, and manage wellness. From AI-powere ...

Pfizer Inc. today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment ...

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine ...

Presentation Title: The ADELA study: A Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA)+ Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2-Advanced Breast Cancer ...

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and ...

Nettle, Radix paeonie, Yanhusuo, Portia cocos, Muli, Cortex mountain, Peach kernel, Szechwan china berry, Sea weed, ...

Following up on a tip to the state’s poaching hotline, game wardens in California rushed to a popular fishing spot, Clifton Court Forebay, in the Sacramento-San Joaquin River Delta. They’d received a ...

Plastic bag ban, wrong food deliveries, streaming services and more. Here's some big changes coming to California as 900 new ...

We hear it more often now. Those tiny particles that scientists can't stop talking about. They're in our water, in our air, ...

Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.

They’re sharp, curious – and prone to boredom or even bullying at school. Far from the smartypants cliches, some gifted ...